JP2015528000A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015528000A5 JP2015528000A5 JP2015521769A JP2015521769A JP2015528000A5 JP 2015528000 A5 JP2015528000 A5 JP 2015528000A5 JP 2015521769 A JP2015521769 A JP 2015521769A JP 2015521769 A JP2015521769 A JP 2015521769A JP 2015528000 A5 JP2015528000 A5 JP 2015528000A5
- Authority
- JP
- Japan
- Prior art keywords
- mcj
- pharmaceutical composition
- disease
- subject
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261670345P | 2012-07-11 | 2012-07-11 | |
| US61/670,345 | 2012-07-11 | ||
| PCT/US2013/049885 WO2014011742A1 (en) | 2012-07-11 | 2013-07-10 | Method and composition for metabolic regulation |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015528000A JP2015528000A (ja) | 2015-09-24 |
| JP2015528000A5 true JP2015528000A5 (https=) | 2016-08-12 |
| JP6442403B2 JP6442403B2 (ja) | 2018-12-19 |
Family
ID=49916526
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015521769A Active JP6442403B2 (ja) | 2012-07-11 | 2013-07-10 | 代謝調節のための方法および組成物 |
Country Status (8)
| Country | Link |
|---|---|
| US (3) | US10583169B2 (https=) |
| EP (2) | EP3936144A1 (https=) |
| JP (1) | JP6442403B2 (https=) |
| CN (2) | CN104582715A (https=) |
| AU (1) | AU2013290266B2 (https=) |
| CA (1) | CA2878829A1 (https=) |
| HK (1) | HK1209650A1 (https=) |
| WO (1) | WO2014011742A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6944373B2 (ja) * | 2015-02-18 | 2021-10-06 | ユニバーシティ・オブ・バーモント・アンド・ステイト・アグリカルチュラル・カレッジＵｎｉｖｅｒｓｉｔｙ Ｏｆ Ｖｅｒｍｏｎｔ Ａｎｄ Ｓｔａｔｅ Ａｇｒｉｃｕｌｔｕｒａｌ Ｃｏｌｌｅｇｅ | Ｍｃｊアゴニストおよびそれらに関する使用 |
| CN108136005A (zh) * | 2015-07-10 | 2018-06-08 | 佛蒙特大学及州农业学院 | 用于治疗药物诱导的疾病和病症的mcj抑制剂 |
| US10694105B1 (en) * | 2018-12-24 | 2020-06-23 | Wipro Limited | Method and system for handling occluded regions in image frame to generate a surround view |
| WO2021168373A1 (en) * | 2020-02-21 | 2021-08-26 | Mitotherapeutix Llc | Compositions and methods for inhibiting expression of methylation-controlled j-protein (mcj) |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3854480A (en) | 1969-04-01 | 1974-12-17 | Alza Corp | Drug-delivery system |
| US4675189A (en) | 1980-11-18 | 1987-06-23 | Syntex (U.S.A.) Inc. | Microencapsulation of water soluble active polypeptides |
| US4452775A (en) | 1982-12-03 | 1984-06-05 | Syntex (U.S.A.) Inc. | Cholesterol matrix delivery system for sustained release of macromolecules |
| US5075109A (en) | 1986-10-24 | 1991-12-24 | Southern Research Institute | Method of potentiating an immune response |
| US5211657A (en) | 1988-11-07 | 1993-05-18 | The United States Government As Represented By The Secretary Of The Department Of Health And Human Services | Laminin a chain deduced amino acid sequence, expression vectors and active synthetic peptides |
| US5133974A (en) | 1989-05-05 | 1992-07-28 | Kv Pharmaceutical Company | Extended release pharmaceutical formulations |
| US5407686A (en) | 1991-11-27 | 1995-04-18 | Sidmak Laboratories, Inc. | Sustained release composition for oral administration of active ingredient |
| EP0804249A2 (en) | 1994-03-15 | 1997-11-05 | Brown University Research Foundation | Polymeric gene delivery system |
| US5736152A (en) | 1995-10-27 | 1998-04-07 | Atrix Laboratories, Inc. | Non-polymeric sustained release delivery system |
| US5922567A (en) * | 1997-06-03 | 1999-07-13 | Incyte Pharmaceuticals, Inc. | Two new human DNAJ-like proteins |
| US6222029B1 (en) | 1997-08-01 | 2001-04-24 | Genset | 5′ ESTs for secreted proteins expressed in brain |
| KR100664587B1 (ko) | 2004-12-22 | 2007-01-04 | 김현기 | 인간 암 억제 유전자, 이에 의해 코딩되는 단백질, 이를포함하는 발현 벡터 및 이 벡터로 형질전환된 세포 |
| WO2007013671A2 (en) * | 2005-07-27 | 2007-02-01 | Oncotherapy Science, Inc. | Method of diagnosing esophageal cancer |
| US20080261217A1 (en) | 2006-10-17 | 2008-10-23 | Melnikov Anatoliy A | Methylation Profile of Cancer |
| US8354237B2 (en) * | 2007-02-02 | 2013-01-15 | University Of Vermont And State Agriculture College | Anti-methylation-controlled j protein antibodies and uses thereof |
-
2013
- 2013-07-10 WO PCT/US2013/049885 patent/WO2014011742A1/en not_active Ceased
- 2013-07-10 US US14/413,927 patent/US10583169B2/en active Active
- 2013-07-10 CN CN201380042721.2A patent/CN104582715A/zh active Pending
- 2013-07-10 CN CN201911091882.6A patent/CN110812470A/zh active Pending
- 2013-07-10 CA CA2878829A patent/CA2878829A1/en not_active Abandoned
- 2013-07-10 JP JP2015521769A patent/JP6442403B2/ja active Active
- 2013-07-10 EP EP21178101.8A patent/EP3936144A1/en not_active Withdrawn
- 2013-07-10 EP EP13817027.9A patent/EP2877198A4/en not_active Ceased
- 2013-07-10 HK HK15110637.1A patent/HK1209650A1/xx unknown
- 2013-07-10 AU AU2013290266A patent/AU2013290266B2/en not_active Ceased
-
2017
- 2017-11-07 US US15/805,534 patent/US10792330B2/en active Active
-
2020
- 2020-10-02 US US17/061,912 patent/US11752193B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Zhang et al. | The SLC transporter in nutrient and metabolic sensing, regulation, and drug development | |
| Biolo et al. | Muscle glutamine depletion in the intensive care unit | |
| Cynober et al. | The 2009 ESPEN Sir David Cuthbertson. Citrulline: a new major signaling molecule or just another player in the pharmaconutrition game? | |
| TWI735546B (zh) | 使用fxr促效劑之方法 | |
| Mattick et al. | Branched‐chain amino acid supplementation: impact on signaling and relevance to critical illness | |
| KR102026342B1 (ko) | 란티오닌 합성효소 c-유사 2-계 치료제 | |
| JP2011503152A5 (https=) | ||
| JP2015528000A5 (https=) | ||
| AU2014413288B2 (en) | Use of composition containing iron (II) amino acid chelate in preparing drug for regulating and controlling fat metabolism | |
| Takeshita et al. | Long-term voluntary exercise, representing habitual exercise, lowers visceral fat and alters plasma amino acid levels in mice | |
| Brasse-Lagnel et al. | Amino acid regulation of mammalian gene expression in the intestine | |
| JP2011105640A (ja) | 気道抵抗改善剤 | |
| CN119700831A (zh) | 鼠李糖乳酪杆菌hpt112在制备预防和/或治疗高尿酸血症药物中的应用 | |
| Lo et al. | The nitric oxide synthase inhibitor NG-nitro-L-arginine methyl ester diminishes the immunomodulatory effects of parental arginine in rats with subacute peritonitis | |
| Kim et al. | Ursolic acid: a promising therapeutic agent for NAFLD via inhibition of SPP1-induced Th17 cell differentiation | |
| Çekmen et al. | The impact of L-alanyl-L-glutamine dipeptide supplemented total parenteral nutrition on clinical outcome in critically patients | |
| Crowell et al. | Marginal dietary zinc deprivation augments sepsis-induced alterations in skeletal muscle TNF-α but not protein synthesis | |
| CN109999019A (zh) | 肉豆蔻脑酸甲酯在制备预防或治疗代谢综合征或改善机体能量代谢的产品中的应用 | |
| Babri et al. | Protective effect of swimming and genistein on the expression of microRNA 132, insulin growth factor 1, and brain-derived neurotrophic factor genes, as well as spatial memory, in the hippocampus of diabetic ovariectomized rats | |
| Lee et al. | Combination treatment of parenteral arginine and nitric oxide inhibitor NG-nitro-L-arginine methyl ester in rats with peritonitis | |
| CN105801663A (zh) | 一种熊果酸小檗碱偶合物的制备方法及医药用途 | |
| US20250177456A1 (en) | Method and composition for preventing and/or treating metabolic disorders | |
| JPWO2019070024A1 (ja) | 肝の線維化を伴い得るｎａｆｌｄモデル動物、その作製方法、及びそれを作製するための飼料 | |
| Frietze et al. | HIF-2α induction in de novo lipogenesis in metabolic dysfunction-associated steatohepatitis is dependent on IL-21 signaling. | |
| RU2018147077A (ru) | Комбинация метаболических биоэнергетических и нутра-эпигенетических регуляторов, нутрицевтических соединений в традиционных и нанотехнологических комбинациях для возвращения в прежнее состояние и предотвращения хронического повреждения, ускоренного клеточной чувствительностью, вызванной сахарным диабетом и другими дегенеративными хроническими комплексными заболеваниями |